These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18632604)

  • 1. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
    Bauerschmitz GJ; Ranki T; Kangasniemi L; Ribacka C; Eriksson M; Porten M; Herrmann I; Ristimäki A; Virkkunen P; Tarkkanen M; Hakkarainen T; Kanerva A; Rein D; Pesonen S; Hemminki A
    Cancer Res; 2008 Jul; 68(14):5533-9. PubMed ID: 18632604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
    Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
    Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene.
    Deng T; Liu JC; Pritchard KI; Eisen A; Zacksenhaus E
    Clin Cancer Res; 2009 Jan; 15(1):119-30. PubMed ID: 19118039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALDH(+)/CD44(+)/CD24(-) expression in cells from body cavity fluids.
    Krishan A; Sharma D; Sharma S; Hamelik RM; Ganjei-Azar P; Nadji M
    Cytometry B Clin Cytom; 2010 May; 78(3):176-82. PubMed ID: 20043317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.
    Abraham BK; Fritz P; McClellan M; Hauptvogel P; Athelogou M; Brauch H
    Clin Cancer Res; 2005 Feb; 11(3):1154-9. PubMed ID: 15709183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
    Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
    Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.
    Eriksson M; Guse K; Bauerschmitz G; Virkkunen P; Tarkkanen M; Tanner M; Hakkarainen T; Kanerva A; Desmond RA; Pesonen S; Hemminki A
    Mol Ther; 2007 Dec; 15(12):2088-93. PubMed ID: 17848962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus based on serotype 3.
    Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
    Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression.
    Zhang Y; Yao F; Yao X; Yi C; Tan C; Wei L; Sun S
    Oncol Rep; 2009 Apr; 21(4):1113-21. PubMed ID: 19288016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
    Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
    Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
    Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells.
    Rivera AA; Davydova J; Schierer S; Wang M; Krasnykh V; Yamamoto M; Curiel DT; Nettelbeck DM
    Gene Ther; 2004 Dec; 11(23):1694-702. PubMed ID: 15496964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.